A patent review of glucokinase activators and disruptors of the glucokinase – glucokinase regulatory protein interaction: 2011 – 2014

Bibliography

• World Health Organization Diabetes Fact Sheet. 2013. Available from: http://www.who.int/mediacentre/factsheets/fs312/en/ [Last accessed 3 March 2014]
   Google Scholar
• Matschinsky FM. Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov 2009;8(5):399-416
   PubMed Web of Science ®Google Scholar
• Fyfe MCT, Procter MJ. Glucokinase activators as potential antidiabetic agents possessing superior glucose-lowering efficacy. Drugs Future 2009;34:641-53
   Web of Science ®Google Scholar
• Matschinsky FM, Magnuson MA. editors. Glucokinase and glycemic disease: from basics to novel therapeutics. S. Karger AG; Basel, Switzerland: 2004
   Google Scholar
• Matschinsky FM. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. Diabetes 1996;45:223-41
   PubMed Web of Science ®Google Scholar
• Del Guerra S, Lupi R, Marselli L, et al. Functional and molecular defects of pancreatic islets in human type 2 diabetes. Diabetes 2005;54:727-35
   PubMed Web of Science ®Google Scholar
• Agius L. Glucokinase and molecular aspects of liver glycogen metabolism. Biochem J 2008;414(1):1-18
   PubMedGoogle Scholar
• Anderka O, Boyken J, Aschenbach U, et al. Biophysical characterization of the interaction between hepatic glucokinase and its regulatory protein: impact of physiological and pharmacological effectors. J Biol Chem 2008;283(46):31333-40
   Google Scholar
• Pautsch A, Stadler N, Lohle A, et al. Crystal structure of glucokinase regulatory protein. Biochemistry 2013;52(20):3523-31
   Google Scholar
• Choi JM, Seo MH, Kyeong HH, et al. Molecular basis for the role of glucokinase regulatory protein as the allosteric switch for glucokinase. Proc Natl Acad Sci USA 2013;110(25):10171-6
   Google Scholar
• Kaminski MT, Schultz J, Waterstradt R, et al. Glucose-induced dissociation of glucokinase from its regulatory protein in the nucleus of hepatocytes prior to nuclear export. Biochim Biophys Acta 2013;1843(3):554-64
   Google Scholar
• Zelent B, Raimondo A, Barrett A, et al. Analysis of the co-operative interaction between the allosterically regulated proteins GK and GKRP using tryptophan fluorescence. Biochem J 2014;459(3):551-64
   Google Scholar
• Cullen KS, Agius L, Al-Oanzi ZH, et al. Glucagon induces translocation of glucokinase from the cytoplasm to the nucleus of hepatocytes by transfer between 6-phosphofructo 2-kinase/fructose 2,6-bisphosphatase-2 and the glucokinase regulatory protein. Biochim Biophys Acta 2014;1843(6):1123-34
   Google Scholar
• Basu A, Basu R, Shah P, et al. Effects of type 2 diabetes on the ability of insulin and glucose to regulate splanchnic and muscle glucose metabolism: evidence for a defect in hepatic glucokinase activity. Diabetes 2000;49(2):272-83
   PubMed Web of Science ®Google Scholar
• Basu A, Basu R, Shah P, et al. Type 2 diabetes impairs splanchnic uptake of glucose but does not alter intestinal glucose absorption during enteral glucose feeding: additional evidence for a defect in hepatic glucokinase activity. Diabetes 2001;50(6):1351-62
   PubMed Web of Science ®Google Scholar
• Caro JF, Triester S, Patel VK, et al. Liver glucokinase: decreased activity in patients with type II diabetes. Horm Metab Res 1995;27:19-22
   PubMed Web of Science ®Google Scholar
• Fujimoto Y, Torres TP, Donahue EP, Shiota M. Glucose toxicity is responsible for the development of impaired regulation of endogenous glucose production and hepatic glucokinase in Zucker diabetic fatty rats. Diabetes 2006;55(9):2479-90
   Google Scholar
• Dunn-Meynell AA, Routh VH, Kang L, et al. Glucokinase is the likely mediator of glucosensing in both glucose-excited and glucose-inhibited central neurons. Diabetes 2002;51(7):2056-65
   PubMed Web of Science ®Google Scholar
• Zelent D, Golson ML, Koeberlein B, et al. A glucose sensor role for glucokinase in anterior pituitary cells. Diabetes 2006;55(7):1923-9
   Google Scholar
• Murphy R, Tura A, Clark PM, et al. Glucokinase, the pancreatic glucose sensor, is not the gut glucose sensor. Diabetologia 2009;52(1):154-9
   PubMed Web of Science ®Google Scholar
• Grimsby J, Sarabu R, Corbett WL, et al. Allosteric activators of glucokinase: Potential role in diabetes therapy. Science 2003;301(5631):370-3
   PubMed Web of Science ®Google Scholar
• Coghlan M, Leighton B. Glucokinase activators in diabetes management. Expert Opin Invest Drugs 2008;17:145-67
   PubMed Web of Science ®Google Scholar
• Filipski KJ, Stevens BD, Pfefferkorn JA. Glucokinase activators in development. In: Jones RM, editor. RSC drug discovery series No 27: new therapeutic stratagies for type 2 diabetes - small molecule approaches. Royal Society of Chemistry, Cambridge, UK; 2012. p. 88-108
   Google Scholar
• Matschinsky FM. GKAs for diabetes therapy: why no clinically useful drug after two decades of trying? Trends Pharmacol Sci 2013;34:90-9
   PubMed Web of Science ®Google Scholar
• Pfefferkorn JA, Guzman-Perez A, Oates PJ, et al. Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus. Med Chem Comm 2011;2(9):828-39
   Google Scholar
• Hinklin RJ, Boyd SA, Chicarelli MJ, et al. Identification of a new class of glucokinase activators through structure-based design. J Med Chem 2013;56(19):7669-78
   Google Scholar
• Pfefferkorn JA. Strategies for the design of hepatoselective glucokinase activators to treat type 2 diabetes. Expert Opin Drug Discov 2013;8(3):319-30
   PubMed Web of Science ®Google Scholar
• Ashton KS, Andrews KL, Bryan MC, et al. Small molecule disruptors of the glucokinase–glucokinase regulatory protein interaction: 1. Discovery of a novel tool compound for in vivo proof-of-concept. J Med Chem 2014;57(2):309-24
   PubMed Web of Science ®Google Scholar
• Sarabu R, Berthel SJ, Kester RF, Tilley JW. Glucokinase activators as new type 2 diabetes therapeutic agents. Expert Opin Ther Pat 2008;18(7):759-68
   Web of Science ®Google Scholar
• Sarabu R, Berthel SJ, Kester RF, Tilley JW. Novel glucokinase activators: a patent review (2008 – 2010). Expert Opin Ther Pat 2011;21(1):13-33
   PubMed Web of Science ®Google Scholar
• Filipski KJ, Futatsugi K, Pfefferkorn JA, Stevens BD. Glucokinase activators. Pharm Pat Anal 2012;1(3):301-11
   Google Scholar
• Advinus Therapeutics Ltd. Acetamide compounds as glucokinase modulators and their preparation and use for treatment and prevention of glucokinase-mediated diseases. WO2012020357; 2012
   Google Scholar
• Advinus Therapeutics Pvt. Ltd. Preparation of acetamide derivatives as glucokinase activators. WO2009047798; 2009
   Google Scholar
• Advinus Therapeutics Ltd. Preparation of acetamide derivatives as glucokinase activators. US20120214735; 2012
   Google Scholar
• Advinus Therapeutics Private Ltd. Preparation of acetamide compounds as glucokinase activators, their process and medicinal applications. EP2402327; 2012
   Google Scholar
• Mitsubishi Tanabe Pharma Corp. Method for the preparation of (E)-hydroxyiminophenylacetic acid derivative. WO2011093423; 2011
   Google Scholar
• Tanabe Seiyaku Co., Ltd. Preparation of oxime compounds as glucokinase activators. JP2010018526; 2010
   Google Scholar
• Tanabe Seiyaku Co., Ltd. Oxime derivatives as glucokinase activating agents and their preparations, pharmaceutical compositions and use in the treatment of diabetes and related diseases. JP2008189659; 2008
   Google Scholar
• Mitsubishi Tanabe Pharma Corp. Preparation of 2-phenyl-2-oxoacetamide oxime derivatives as glucokinase activator for treatment of diabetes, diabetic complication, and obesity. WO2008084873; 2008
   Google Scholar
• Tanabe Seiyaku Co., Ltd. Oxime derivatives as glucokinase activating agents and their preparations, pharmaceutical compositions and use in the treatment of diabetes and related diseases. WO2007007886; 2007
   Google Scholar
• F. Hoffmann-La Roche AG. Preparation of 3-oxo-3,9-dihydro-1H-chromeno[2,3-c]pyrroles as glucokinase activators for treating metabolic diseases. WO2011157682; 2011
   Google Scholar
• F. Hoffmann-La Roche AG. Pyrrolidinone as glucokinase activators and their preparation, pharmaceutical compositions and use in the treatment of metabolic disorders. WO2009127546; 2009
   Google Scholar
• F. Hoffmann-La Roche AG. Preparation of isoindolinone derivatives as glucokinase activators for treating metabolic diseases. WO2012150202; 2012
   Google Scholar
• F. Hoffmann-La Roche A.-G. Isoindolin-1-one glucokinase activators, and their pharmaceutical compositions, preparation, and use in the treatment or prophylaxis of type II diabetes. WO2002048106; 2002
   Google Scholar
• Hoffmann-La Roche, Inc. Isatin and oxindole compounds as glucokinase activators and their preparation and use in the treatment of diabetes. US20120142705; 2012
   Google Scholar
• Takeda Pharmaceutical Co., Ltd. Method of making azaindazole derivatives. WO2012051450; 2012
   Google Scholar
• Takeda San Diego, Inc. Preparation of pyrazolyl amides as glucokinase activators. WO2009140624; 2009
   Google Scholar
• Transtech Pharma, Inc. The use of metformin in combination with a glucokinase activator for antidiabetic pharmaceutical compositions. WO2011149945; 2011
   Google Scholar
• Novo Nordisk A/S. Preparation of heteroaryl ureas and their use as glucokinase activators. WO2005066145; 2005
   Google Scholar
• TransTech Pharma press release Feb 20, 2007: TransTech Pharma, Inc. obtains entire GKA program for diabetes from Novo Nordisk. Available from: http://www.ttpharma.com/PressReleases/2007/20070220TransTechPharmaInc/tabid/195/Default.aspx [Last accessed 12 February 2014]
   Google Scholar
• TransTech Pharma, Inc. Glucokinase activator compositions for the treatment of diabetes and related disorders. WO2013173417; 2013
   Google Scholar
• Kowa Co., Ltd. Preparation of spiroindoline compounds for activating glucokinase. WO2013057944; 2013
   Google Scholar
• AstraZeneca AB; AstraZeneca UK Ltd. Preparation of a glucokinase activator and pharmaceutical formulations. WO2012007758; 2012
   Google Scholar
• Waring MJ, Clarke DS, Fenwick MD, et al. Property based optimisation of glucokinase activators - discovery of the phase IIb clinical candidate AZD1656. Med Chem Comm 2012;3(9):1077-81
   Google Scholar
• Pfizer, Inc. 2-(3,5-Disubstitutedphenyl)pyrimidin-4(3H)-one derivatives as glucokinase activators and their preparation and use in the treatment of diabetes. WO2011158149; 2011
   Google Scholar
• Filipski KJ, Guzman-Perez A, Bian J, et al. Pyrimidone-based series of glucokinase activators with alternative donor-acceptor motif. Bioorg Med Chem Lett 2013;23:4571-8
   Google Scholar
• Cadila Healthcare Ltd. N-Thiazolyl benzamide derivatives as glucokinase activators and their preparation and use in the treatment of type II diabetes. WO2010150280; 2010
   Google Scholar
• Cadila Healthcare Ltd. Substituted benzamide derivatives as glucokinase (GK) activators and their preparation. WO2011013141; 2011
   Google Scholar
• Cadila Healthcare Ltd. Novel compounds for treatment for diabetes. IN2012MU01500; 2014
   Google Scholar
• Array BioPharma, Inc.; Amgen, Inc. Urea compounds as GKa activators and their preparation. WO2013086397; 2013
   Google Scholar
• Zhejiang Beta Pharma, Inc. Preparation of pyridinyloxypyridinylaminobenzene derivatives for use as glucokinase active modulators. WO2012062210; 2012
   Google Scholar
• Daiichi Sankyo Co., Ltd. Preparation of 2,5-disubstituted pyrrole compounds containing oxazoline moiety as glucokinase (GK) activators. JP2012020960; 2012
   Google Scholar
• Daiichi Sankyo Co., Ltd. Phenylpyrrole derivative crystal, is preparation, and use for pharmaceutical compositions and preventive or therapeutic agent for diabetes mellitus or glucose intolerance. WO2012147832; 2012
   Google Scholar
• Daiichi Sankyo Co., Ltd. Preparation of novel 2-phenylpyrrole derivatives as glucokinase activators. WO2009099080; 2009
   Google Scholar
• Daiichi Sankyo Co., Ltd. Preparation of dipyridylamine derivatives as glucokinase-activating agents. WO2012121314; 2012
   Google Scholar
• Sanwa Kagaku Kenkyusho Co., Ltd. Preparation of thiophenecarboxamide derivatives for use as glucokinase activators in medicine. WO2011162267; 2011
   Google Scholar
• Sanwa Kagaku Kenkyusho Co., Ltd. Preparation of thiophene-carboxamide derivatives as glucokinase activators. WO2010150899; 2010
   Google Scholar
• Institute of Materia Medica, Chinese Academy of Medical Sciences. Preparation of thiazole-5-formamide derivatives for treating glucokinase-related diseases. CN102532123; 2012
   Google Scholar
• Institute of Materia Medica, Chinese Academy of Medical Sciences. Pyrimidine derivatives as glucokinase activators and their preparation, pharmaceutical compositions and use in the treatment of diseases. CN102558149; 2012
   Google Scholar
• Institute of Materia Medica, Chinese Academy of Medical Sciences. Preparation of thiazolidinedione derivatives as dual agonists of glucokinase and peroxisome proliferator-activated receptors. CN102558167; 2012
   Google Scholar
• Institute of Materia Medica, Chinese Academy of Medical Sciences. (Aryl)urea derivatives with agonistic activity of GK and PPAR and their preparation, pharmaceutical compositions and use in the treatment of diabetes mellitus. CN102718703; 2012
   Google Scholar
• Institute of Materia Medica, Chinese Academy of Medical Sciences. Preparation of arylurea derivatives with agonist activity of GK and PPAR. CN102718727; 2012
   Google Scholar
• Institute of Materia Medica, Chinese Academy of Medical Sciences. Preparation of pyrimidyl-thiazolylamine derivatives with GK and PPAR dual agonist activities. CN102786517; 2012
   Google Scholar
• Institute of Materia Medica, Chinese Academy of Medical Sciences. Lignin-like compounds with glucose kinase-activating activity. CN102557893; 2012
   Google Scholar
• Amgen, Inc. Preparation of sulfonylpiperazine derivatives that interact with glucokinase regulatory protein for the treatment of diabetes and other diseases. WO2012027261; 2012
   Google Scholar
• Lloyd DJ, St Jean DJ Jr, Kurzeja RJM, et al. Antidiabetic effects of glucokinase regulatory protein small-molecule disruptors. Nature 2013;504:437-40
   PubMed Web of Science ®Google Scholar
• St. Jean DJ, Ashton KS, Bartberger MD, et al. Small molecule disruptors of the glucokinase–glucokinase regulatory protein interaction: 2. Leveraging structure-based drug design to identify analogues with improved pharmacokinetic profiles. J Med Chem 2014;57(2):325-38
   Google Scholar
• Amgen, Inc. Preparation of cyclic sulfonyl compounds that interact with glucokinase regulatory protein for use in treating type 2 diabetes and other diseases. WO2013123444; 2013
   Google Scholar
• Amgen, Inc. Preparation of benzodioxepine and benzodioxine compounds that interact with glucokinase regulatory protein for the treatment of diabetes. WO2012138776; 2012
   Google Scholar
• Amgen, Inc. Preparation of benzothiophene sulfonamides and related compounds that interact with glucokinase regulatory protein. WO2013173382; 2013
   Google Scholar
• Advinus pipeline. Available from: http://www.advinus.com/pipeline.asp [Last accessed 20 March 2014]
   Google Scholar
• Array BioPharma news release Aug 7, 2013: Array BioPharma reports financial results for the fourth quarter and full year of fiscal 2013. Available from: http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-newsArticle&ID=1845712&highlight= [Last accessed 12 February 2014]
   Google Scholar
• Amgen phase 2 trial of AMG 151. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01464437 [Last accessed 12 February 2014]
   Google Scholar
• Sjöstrand M, Ericsson H, Hartford M, et al. Pharmacodynamic effects of the oral glucokinase activator AZD6370 after single doses in healthy volunteers assessed with euglycaemic clamp. Diabetes Obes Metab 2013;15(1):35-41
   Google Scholar
• Ericsson H, Roshammar D, Wollbratt M, et al. Tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator AZD1656, after single ascending doses in healthy subjects during euglycemic clamp. Int J Clin Pharmacol Ther 2012;50:765-77
   Google Scholar
• AstraZeneca AB; AstraZeneca UK Ltd. Preparation of 3-{[5-(azetidin-1-ylcarbonyl)pyrazin-2-yl]loxy}-5-{[(1S)-2-hydroxy-1-methylethyl]oxy}-N-(5-methylpyrazin-2-yl)benzamide monohydrate as activator of glucokinase. WO2011135355; 2011
   Google Scholar
• Wilding JPH, Leonsson-Zachrisson M, Wessman C, Johnsson E. Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin. Diabetes Obes Metab 2013;15:750-9
   PubMed Web of Science ®Google Scholar
• Kiyosue A, Hayashi N, Komori H, et al. Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2013;15:923-30
   PubMed Web of Science ®Google Scholar
• Daiichi-Sankyo pipeline as of Jan 2014. Available from: http://www.daiichisankyo.com/rd/pipeline/pdf/Pipeline_EN.pdf [Last accessed 20 March 2014]
   Google Scholar
• Hua Medicine HMS5552 research overview. Available from: http://www.huamedicine.com/research1.htm [Last accessed 20 March 2014]
   Google Scholar
• Sarabu R, Bizzarro FT, Corbett WL, et al. Discovery of piragliatin—first glucokinase activator studied in type 2 diabetic patients. J Med Chem 2012;55(16):7021-36
   PubMed Web of Science ®Google Scholar
• Meininger GE, Scott R, Alba M, et al. Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care 2011;34(12):2560-6
   PubMed Web of Science ®Google Scholar
• Klapars A, Campos KR, Waldman JH, et al. Enantioselective Pd-catalyzed alpha-arylation of N-Boc-pyrrolidine: the key to an efficient and practical synthesis of a glucokinase activator. J Org Chem 2008;73:4986-93
   PubMed Web of Science ®Google Scholar
• Magnus NA, Braden TM, Buser JY, et al. Development of an enantioselective hydrogenation based synthesis of a glucokinase activator. Org Process Res Dev 2012;16(5):830-5
   Google Scholar
• Yamagami T, Moriyama N, Kyuhara M, et al. Scalable synthesis of a nonracemic alpha-arylpropionic acid via ketene desymmetrization for a glucokinase activator. Org Process Res Dev 2014;18(3):437-45
   Google Scholar
• Assessing metabolite coverage of LY2608204 human metabolites in chronic rat and dog toxicology studies. Lilly poster presented at the 15th Annual Land O’ Lakes Conference; 10 – 14 September 2012; Merrimac, WI. Available from: www.xbl.com/uploads/papers_poster_35_3984033172.pdf [ Last accessed 12 February 2014]
   Google Scholar
• Lilly phase 2 trial of LY2608204. Available from: http://clinicaltrials.gov/ct2/show/NCT01408095 [Last accessed 12 February 2014]
   Google Scholar
• Pfizer phase 1 study of two dosing regimens of PF-04937319. Available from: http://www.clinicaltrials.gov/ct2/show/study/NCT01933672 [Last accessed 12 February 2014]
   Google Scholar
• Pfizer pipeline as of February 28, 2014. Available from: http://www.pfizer.com/research/science_and_technology/product_pipeline [Last accessed 20 March 2014]
   Google Scholar
• Pfizer phase 2 study of PF-04937319 in type 2 diabetics versus sitagliptin. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01475461 [Last accessed 12 February 2014]
   Google Scholar
• Pfizer phase 2 study of PF-04937319 versus glimeperide. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01517373 [Last accessed 12 February 2014]
   Google Scholar
• Pfizer pipeline as of May 10, 2012. Available from: http://www.pfizer.com/research/science_and_technology/product_pipeline/past_pipelines [Last accessed 12 February 2014]
   Google Scholar
• Pfizer pipeline as of Aug 9, 2012. Available from: http://www.pfizer.com/research/science_and_technology/product_pipeline/past_pipelines [Last accessed 12 February 2014]
   Google Scholar
• Pfefferkorn JA, Guzman-Perez A, Litchfield J, et al. Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus. J Med Chem 2012;55(3):1318-33
   Google Scholar
• Kazierad DJ, Bergman AJ, Pfefferkorn JA, et al. Pharmacokinetics and pharmacodynamics of PF-04991532, a hepatoselective glucokinase activator (GKA), administered as monotherapy in Japanese and non-Japanese T2DM patients [1050-P]. ADA 73rd Scientific Sessions; 21–25 June 2013; Chicago, IL
   Google Scholar
• Kazierad DJ, Pfefferkorn JA, Bergman A, et al. The hepatoselective glucokinase activator, PF-04991532, lowers HbA1c after 12 weeks of dosing in patients with type 2 diabetes [1051-P]. ADA 73rd Scientific Sessions; 21 – 25 June 2013; Chicago, IL
   Google Scholar
• Pfizer phase 2 trial of b.i.d. PF-04991532 in type 2 diabetics. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01338870 [Last accessed 12 February 2014]
   Google Scholar
• Pfizer phase 2 trial of q.d. PF-04991532 in type 2 diabetics. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01336738 [Last accessed 12 February 2014]
   Google Scholar
• Haynes N-E, Corbett WL, Bizzarro FT, et al. Discovery, structure−activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2-yl-propionamide (RO0281675). J Med Chem 2010;53(9):3618-25
   PubMed Web of Science ®Google Scholar
• Guertin KR. Allosteric activators of glucokinase (GK) for the treatment of type 2 diabetes. In: Ward RA, Goldberg F, editors. RSC drug discovery series No 19: kinase drug discovery. Royal Society of Chemistry; Cambridge, UK: 2011. p. 244-61
   Google Scholar
• Qian Y, Corbett WL, Berthel SJ, et al. Identification of RO4597014, a glucokinase activator studied in the clinic for the treatment of type 2 diabetes. ACS Medicinal Chemistry Letters 2013;4(4):414-18
   Google Scholar
• Roche 2008 pipeline. Available from: www.roche.com/gb07erd.pdf [Last accessed 12 February 2014]
   Google Scholar
• Bachmann S, Fettes A, Lautz C, Scalone M. Glucokinase activator: practical asymmetric hydrogenation and scalable synthesis of an API fragment. Org Process Res Dev 2013;17(11):1451-7
   Google Scholar
• F. Hoffmann-La Roche AG. Preparation of glucokinase activator compound. WO2011023706; 2011
   Google Scholar
• Takeda R&D pipeline as of February 5, 2014. Available from: http://www.takeda.com/research/pipeline/ [Last accessed 12 February 2014]
   Google Scholar
• TransTech Pharma press release August 14, 2013: first liver-selective glucokinase activator for type 2 diabetes demonstrates normalized HbA1c and no hypoglycemia in clinical trials. Available from: http://www.ttpharma.com/PressReleases/2013/20130814TransTechPharmaPressRelease/tabid/253/Default.aspx [Last accessed 12 February 2014]
   Google Scholar
• TransTech Pharma diabetes pipeline. Available from: http://www.ttpharma.com/TherapeuticAreas/MetabolicDiseases/Diabetes/tabid/89/Default.aspx [Last accessed 20 March 2014]
   Google Scholar
• Zydus Cadila discovery pipeline. Available from: http://www.zyduscadila.com/discovery.html [Last accessed 12 February 2014]
   Google Scholar